In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With DxS, Qiagen Moves into Personalized Medicine

Executive Summary

Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.
Advertisement

Related Content

Companion Diagnostics Move Toward Mainstream Drug Development
Companion Diagnostics Move Toward Mainstream Drug Development
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009
What New Her2 Tests Say about Personalized Medicine
Her2 Testing: What's Old Is New
Her2 Testing: What's Old Is New
Does Roche Have It Right?
Does Roche Have It Right?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel